Reshma Kewalramani, an officer and director of Vertex Pharmaceuticals Inc / MA, filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 11,866 shares of Vertex common stock with an aggregate market value of $6,307,134.98.

Key Highlights

  • Proposed sale size: 11,866 shares of Vertex Pharmaceuticals common stock, with an aggregate market value of $6,307,134.98.
  • Seller: Reshma Kewalramani, identified in the filing as both an officer and a director of the issuer.
  • Shares outstanding: The filing reports 253,537,674 shares of common stock outstanding.
  • Broker: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is named as the executing broker.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan or instruction was adopted on August 5, 2026.
  • No sales in past 3 months: The filing states "Nothing to Report" for securities sold during the past three months.
  • Approximate sale date: November 6, 2026, on NASDAQ.

Acquisition History and Proposed Sale Details for Kewalramani's Vertex Holdings

According to the Form 144 filing, the 11,866 shares proposed for sale by Reshma Kewalramani were accumulated through four separate acquisition transactions. Two involved Employee Stock Purchase Plan (ESPP) purchases directly from the issuer: 69 shares acquired on May 14, 2024, for cash, and 53 shares acquired on May 14, 2025, for cash. The remaining shares came from restricted stock vestings: 1,744 shares vested on February 24, 2025, as compensation, and 10,000 shares vested on August 6, 2025, also as compensation.

The filing was submitted with a date of notice of November 6, 2026, and indicates reliance on a Rule 10b5-1 plan or instruction with an adoption date of August 5, 2026. The notice was signed by Wade Moss as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Reshma Kewalramani. No securities of Vertex were reported as sold by Kewalramani in the three months preceding this notice, per the filing.

Vertex Pharmaceuticals Inc / MA is listed on NASDAQ (SEC File Number 000-19319) and is headquartered at 50 Northern Avenue, Boston, Massachusetts 02210. The filing does not disclose a per-share sale price; the aggregate market value of $6,307,134.98 is stated for the 11,866 shares proposed for sale.

What Was Disclosed

Reshma Kewalramani, an officer and director of Vertex Pharmaceuticals, filed a Form 144 notice proposing to sell 11,866 common shares with an aggregate market value of $6,307,134.98, acquired via ESPP purchases and restricted stock vestings, through Fidelity Brokerage Services LLC on NASDAQ.